Aura Biosciences Inc (AURA) Stock Price, Quote & News

Company Profile

Aura Biosciences, Inc., a clinical-stage biotechnology company, develops precision therapies to treat solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates. Its lead candidate is bel-sar, which is in late-stage clinical development for the treatment of patients with primary choroidal melanoma and other ocular oncology indications, as well...

Industry: Biotechnology

Sector: Healthcare

Phone: 617 500 8864

Website: www.aurabiosciences.com

Address:

80 Guest Street, 5th Floor, Boston, United States

OnlyFibs Apr. 11 at 3:43 AM

$AURA 1W — 3-year descending channel. $25 → $4.35 (83% drawdown). RSI hit sub-20 at the low. Then: breakout from the channel in early 2025 on the highest volume in years. Blue MA turned UP for the first time since 2021. Now doing a classic channel breakout retest at the orange band $6.00–$6.60. VPVR is densest right here at $6.00–$7.17. Air pocket above to $8.57 → $9.42. 🔴 Res: $7.17 / $8.57 / $9.42 🟢 Sup: $6.60 / $6.07 orange band / $5.10 Hold the retest = continuation. Lose $6 = false breakout. Small-cap biotech with binary catalyst risk. Watch this one. #AURA #Biotech #hovdid

0 · Reply

JMJTrading Mar. 30 at 6:45 PM

$BFRG Shares are rising on Monday’s opening trade after the company announced a deal with a major global pharmaceutical giant! Bullfrog AI stated that its agreement requires the company to use its bfLEAP program to identify and prioritize novel drug targets in major depressive disorder (MDD). The company stated that this is aimed at accelerating its drug discovery and clinical development programs. - Very bullish. @TeamBullish @DavidScott @Ultra_Calls $AURA $PRGS

0 · Reply

d_risk Mar. 30 at 2:58 PM

$AURA - Aura Biosciences Inc - 10K - Updated Risk Factors AURA now faces explicit “substantial doubt” about its ability to continue as a going concern, with a going-concern audit opinion, heightened dependence on new financing (including warrants), expanded geopolitical/tariff and tax-law risks, new AI governance and cybersecurity threats, and more complex global data/privacy and EU regulatory changes. #Biotechnology #FinancialRisk #GeopoliticalRisk #AIGovernance #DataPrivacy 🟢 Added 🟠 Removed https://d-risk.ai/AURA/10-K/2026-03-30

0 · Reply

rando321456 Mar. 30 at 1:11 AM

$AURA $CLSD To me what's so interesting about aura bidding so aggressively for the royalties is that they have to have confidence that Bel-Sar's revenue stream alone will repay HCR relatively fast. We're talking maybe about 3-4% net flow throughs.

1 · Reply

Ml55totoag Mar. 17 at 4:55 PM

$AURA must be nice when insiders are selling. wtf!

1 · Reply

IM2SOLO4U Mar. 16 at 10:46 PM

$AURA WHAT'S GOING ON HERE VERY QUIET LOOKS GOOD ANYONE HERE TO CHAT ABOUT THIS ONE

1 · Reply

Freddie___Mac Mar. 16 at 9:01 PM

$AURA coiled spring. should go a lot higher

0 · Reply

rando321456 Mar. 16 at 8:44 PM

$AURA Surprised at how quiet everything is on this board

0 · Reply

Uromaster Mar. 16 at 4:57 PM

$AURA This is an entirely overlooked stock. Good data.

0 · Reply

BillionerOfKing Mar. 10 at 5:17 PM

$AURA Current Stock Price: $5.68 Contracts to trade: $5.0 AURA Mar 20 2026 Call Entry: $1.08 Exit: $2.13 ROI: 97% Hold ~20 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts

0 · Reply

Aura Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights

Nov 24, 2025, 4:05 PM EST - 5 months ago

Aura Biosciences to Participate in the 8th Annual Evercore Healthcare Conference

Nov 13, 2025, 7:00 AM EST - 5 months ago

Aura Biosciences Reports Third Quarter 2025 Financial Results and Business Highlights

Sep 3, 2025, 7:00 AM EDT - 7 months ago

Aura Biosciences to Participate in the H.C. Wainwright 27th Annual Global Investment Conference

Aug 13, 2025, 7:00 AM EDT - 8 months ago

Aura Biosciences Reports Second Quarter 2025 Financial Results and Business Highlights

May 15, 2025, 9:32 AM EDT - 11 months ago

Aura Biosciences Announces Pricing of Public Offering of Common Stock and Warrants

May 15, 2025, 6:10 AM EDT - 11 months ago

Aura Biosciences Announces Proposed Public Offering of Common Stock and Warrants

May 15, 2025, 6:01 AM EDT - 11 months ago

Aura Biosciences Reports First Quarter 2025 Financial Results and Business Highlights

May 1, 2025, 4:01 PM EDT - 1 year ago

Aura Biosciences to Participate in Upcoming Investor Conferences

Apr 2, 2025, 7:00 AM EDT - 1 year ago

Aura Biosciences Announces Appointment of Teresa Bitetti to Board of Directors

Mar 24, 2025, 4:01 PM EDT - 1 year ago

Aura Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results and Business Highlights

Mar 24, 2025, 7:00 AM EDT - 1 year ago

Positive Data from Phase 1 Trial of Bel-sar in Patients with Non-Muscle-Invasive Bladder Cancer (NMIBC) Presented at the 40th Annual European Association of Urology Congress

Mar 3, 2025, 7:00 AM EST - 1 year ago

Aura Biosciences Announces Additional Data from Ongoing Phase 1 Trial in Non-Muscle Invasive Bladder Cancer to be Presented as a Late-Breaking Abstract at the 40th Annual European Association of Urology Congress

Dec 2, 2024, 4:31 AM EST - 1 year ago

Muscle Invasive Bladder Cancer Drug Pipeline Market Research 2024 Featuring Aura Biosciences, Janssen Research & Development, Asieris Pharmaceuticals, and RemeGen

Oct 18, 2024, 9:16 AM EDT - 1 year ago

Aura Biosciences' Bladder Cancer Candidate Demonstrates Tumor Shrinkage In Patients With High-Grade Disease

Oct 17, 2024, 4:05 PM EDT - 1 year ago

Multiple Clinical Complete Responses Demonstrated Following Single Low Dose Administration of Bel-sar in Patients with Non-Muscle-Invasive Bladder Cancer (NMIBC) in Ongoing Phase 1 Trial

Oct 15, 2024, 12:40 PM EDT - 1 year ago

3 Small-Cap Stocks Ready to Deliver Significant Growth

FBRT TZOO

Sep 12, 2024, 11:40 AM EDT - 1 year ago

Aura Biosciences Touts Promising Data From Eye Cancer Candidate

Sep 12, 2024, 6:30 AM EDT - 1 year ago

Aura Biosciences Reports Positive Phase 2 End of Study Results Evaluating Bel-sar as a First-Line Treatment for Early-Stage Choroidal Melanoma

Sep 3, 2024, 4:05 PM EDT - 1 year ago

Aura Biosciences to Host a Urologic Oncology Investor Event to Present Early Non-Muscle Invasive Bladder Cancer (NMIBC) Data from its Ongoing Phase 1 Trial on Thursday, October 17, 2024

Aug 26, 2024, 4:05 PM EDT - 1 year ago

Aura Biosciences Announces the Presentation of Phase 2 End of Study Data Evaluating Suprachoroidal Administration of Bel-sar for the First-Line Treatment of Patients with Early-Stage Choroidal Melanoma at The Retina Society Annual Meeting

Aug 8, 2024, 7:00 AM EDT - 1 year ago

Aura Biosciences Reports Second Quarter 2024 Financial Results and Business Highlights

May 30, 2024, 4:05 PM EDT - 2 years ago

Aura Biosciences to Participate in the Jefferies Global Healthcare Conference

May 23, 2024, 8:00 AM EDT - 2 years ago

Aura Biosciences to Host Virtual KOL Event “Pioneering a New Standard of Care In Ocular Oncology” on May 29, 2024

May 9, 2024, 7:00 AM EDT - 2 years ago

Aura Biosciences Reports First Quarter 2024 Financial Results and Business Highlights

Mar 27, 2024, 7:00 AM EDT - 2 years ago

Aura Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights

Dec 7, 2023, 8:00 AM EST - 2 years ago

Aura Biosciences Announces First Patient Dosed in Global Phase 3 CoMpass Trial Evaluating the Safety and Efficacy of Belzupacap Sarotalocan (Bel-sar) for First-Line Treatment of Early-Stage Choroidal Melanoma

Nov 9, 2023, 4:05 PM EST - 2 years ago

Aura Biosciences Reports Third Quarter 2023 Financial Results and Provides Clinical Development and Operational Highlights

Nov 6, 2023, 10:02 PM EST - 2 years ago

Aura Biosciences Announces Pricing of Public Offering of Common Stock

Nov 6, 2023, 4:08 PM EST - 2 years ago

Aura Biosciences Announces Proposed Public Offering of Common Stock

Nov 6, 2023, 3:00 PM EST - 2 years ago

Aura Biosciences Receives FDA Agreement Under Special Protocol Assessment (SPA) for CoMpass Phase 3 Clinical Trial of Belzupacap Sarotalocan (Bel-sar) in Early-stage Choroidal Melanoma

Oct 31, 2023, 4:05 PM EDT - 2 years ago

Aura Biosciences to Present Updated Phase 2 Data Evaluating Suprachoroidal Administration of Belzupacap Sarotalocan (Bel-sar) for the First-Line Treatment of Patients with Early-Stage Choroidal Melanoma at AAO 2023

Oct 2, 2023, 4:05 PM EDT - 2 years ago

Aura Biosciences Strengthens and Expands Leadership Team with Key Appointments

Aug 9, 2023, 7:00 AM EDT - 2 years ago

Aura Biosciences Reports Second Quarter 2023 Financial Results and Provides Clinical Development and Operational Highlights

May 12, 2023, 7:00 AM EDT - 3 years ago

Aura Biosciences to Participate in the JMP Securities Life Sciences Conference

May 11, 2023, 4:10 PM EDT - 3 years ago

Aura Biosciences Reports First Quarter 2023 Financial Results and Provides Clinical Development and Operational Highlights

Mar 15, 2023, 4:10 PM EDT - 3 years ago

Aura Biosciences Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Clinical Development and Operational Highlights

Feb 16, 2023, 7:00 AM EST - 3 years ago

Aura Biosciences Announces Positive Interim Phase 2 Safety and Efficacy Data of Belzupacap Sarotalocan (Bel-sar) for the First-Line Treatment of Patients with Early-Stage Choroidal Melanoma with Suprachoroidal Administration

Nov 10, 2022, 7:00 AM EST - 3 years ago

Aura Biosciences Reports Third Quarter 2022 Financial Results and Provides Clinical Development and Operational Highlights

Nov 10, 2022, 6:45 AM EST - 3 years ago

Aura Announces Global Phase 3 Trial Design with Suprachoroidal Route of Administration Based on Positive Phase 2 Interim Data of Belzupacap Sarotalocan in Early-Stage Choroidal Melanoma

Oct 3, 2022, 7:00 AM EDT - 3 years ago

Aura Biosciences Announces Interim Phase 2 Data Evaluating Suprachoroidal Administration of Belzupacap Sarotalocan (AU-011) for the First-Line Treatment of Patients with Early-Stage Choroidal Melanoma Presented at AAO 2022

Sep 28, 2022, 7:00 AM EDT - 3 years ago

Aura Biosciences Announces First Patient Dosed in Phase 1 Study Evaluating Belzupacap Sarotalocan (AU-011) for the Treatment of Non-Muscle Invasive Bladder Cancer

Sep 27, 2022, 7:00 AM EDT - 3 years ago

Aura Biosciences to Present Ongoing Phase 2 Data Evaluating Suprachoroidal Administration of Belzupacap Sarotalocan (AU-011) for the First-Line Treatment of Patients with Early-Stage Choroidal Melanoma at AAO 2022

Sep 7, 2022, 7:00 AM EDT - 3 years ago

Aura Biosciences to Present Phase 2 Safety Data Evaluating Suprachoroidal Administration of Belzupacap Sarotalocan (AU-011) in Patients with Choroidal Melanoma at the ESMO 2022 Congress

Sep 1, 2022, 7:00 AM EDT - 3 years ago

Aura Biosciences to Present Belzupacap Sarotalocan (AU-011) Data from Multiple Studies at the 22nd EURETINA Congress

Aug 11, 2022, 4:15 PM EDT - 3 years ago

Aura Biosciences Reports Second Quarter 2022 Financial Results and Provides Clinical Development and Operational Highlights

Aug 2, 2022, 7:00 AM EDT - 4 years ago

Aura Biosciences to Participate at the 2022 BTIG Biotechnology Conference

Jul 19, 2022, 3:06 PM EDT - 4 years ago

JMP Is Bullish On This Cancer Stock "Sees New Way to Treat Cancer"

Jun 30, 2022, 8:51 AM EDT - 4 years ago

Aura's stock jumps 11% after announcing Fast Track status for its bladder cancer treatment candidate

Jun 30, 2022, 7:00 AM EDT - 4 years ago

Aura Biosciences Receives FDA Fast Track Designation for Belzupacap Sarotalocan (AU-011) for the Treatment of Non-Muscle Invasive Bladder Cancer

OnlyFibs Apr. 11 at 3:43 AM

0 · Reply

JMJTrading Mar. 30 at 6:45 PM

0 · Reply

d_risk Mar. 30 at 2:58 PM

0 · Reply

rando321456 Mar. 30 at 1:11 AM

1 · Reply

Ml55totoag Mar. 17 at 4:55 PM

$AURA must be nice when insiders are selling. wtf!

1 · Reply

IM2SOLO4U Mar. 16 at 10:46 PM

$AURA WHAT'S GOING ON HERE VERY QUIET LOOKS GOOD ANYONE HERE TO CHAT ABOUT THIS ONE

1 · Reply

Freddie___Mac Mar. 16 at 9:01 PM

$AURA coiled spring. should go a lot higher

0 · Reply

rando321456 Mar. 16 at 8:44 PM

$AURA Surprised at how quiet everything is on this board

0 · Reply

Uromaster Mar. 16 at 4:57 PM

$AURA This is an entirely overlooked stock. Good data.

0 · Reply

BillionerOfKing Mar. 10 at 5:17 PM

0 · Reply

OfficialStocktwitsUser Feb. 13 at 8:15 PM

$AURA RSI: 54.31, MACD: 0.0328 Vol: 0.25, MA20: 5.57, MA50: 5.70 🟢 BUY - Uptrend + healthy RSI 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.

0 · Reply

OfficialStocktwitsUser Jan. 21 at 2:21 PM

$AURA RSI: 33.56, MACD: -0.2448 Vol: 0.36, MA20: 5.39, MA50: 5.72 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.

0 · Reply

garygb Jan. 5 at 8:55 PM

$AURA Excited about this one.

0 · Reply

garygb Jan. 5 at 5:33 PM

$AURA great entry spot

0 · Reply

BillionerOfKing Jan. 2 at 5:51 PM

$AURA Current Stock Price: $5.21 Contracts to trade: $5 AURA Jan 16 2026 Call Entry: $0.40 Exit: $0.58 ROI: 45% Hold ~26 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts

0 · Reply

OnlyFibs Dec. 28 at 4:00 AM

$AURA back-tests its structural floor at $5.81. Between the Phase 3 CoMpass trial momentum and the 86% institutional anchor, the fundamental floor is completely disconnected from the current price. The Setup: Textbook 8h bottoming signs with surging buy volume. We need that final "push" through $6.11 to confirm the next leg up. Bull Level: A high-volume breakout targets the $23.00 max estimate. Bear Safety: The absolute Line in the Sand is $4.35. Break it and we’re out. Catalyst: Initial data from the mid-2026 bladder cancer trial is the next massive institutional trigger. 🚢📉 #hovdid

0 · Reply

GlobalNorthN Dec. 25 at 2:54 PM

$AURA This ticker is entering a stage where execution quality will overshadow headline narratives. Margin stability needs to accompany any growth acceleration. Momentum becomes sustainable only with dependable execution. Patience is reasonable — but it must be matched by tangible progress.

0 · Reply

johsmith Dec. 24 at 1:27 PM

$AURA Identified as buy candidate. Still waiting a bit. But great opportunity in my eyes.

0 · Reply

SuperGreenToday Dec. 11 at 8:58 PM

$AURA Share Price: $6.53 Contract Selected: Jul 17, 2026 $7.5 Calls Buy Zone: $0.51 – $0.63 Target Zone: $0.96 – $1.17 Potential Upside: 78% ROI Time to Expiration: 217 Days | Updates via https://fxcapta.com/stockinfo/

0 · Reply

JarvisFlow Nov. 26 at 12:15 PM

Evercore ISI Group updates rating for Aura Biosciences ( $AURA ) to Outperform, target set at 13.

0 · Reply

BillionerOfKing Oct. 14 at 2:05 PM

$AURA Current Stock Price: $6.08 Contracts to trade: $5 AURA Oct 17 2025 Call Entry: $1.71 Exit: $2.71 ROI: 58% Hold ~20 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts

0 · Reply

Buysellbkr Oct. 13 at 10:26 PM

$AURA lets get 1.50

1 · Reply

Market Cap	436.22M
Revenue (ttm)	0.00
Net Income (ttm)	-106.19M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	337,000
Avg Vol	265,194
Day's Range	N/A - N/A
Shares Out	64.15M
Stochastic %K	82%
Beta	0.35
Analysts	Strong Sell
Price Target	$20.20